1. Generics Bulletin
  2. >>Legal & IP

Teva Hit By US Suit Over Copaxone Copays

DoJ Pursues Israeli Generics Giant Over Charity Payments

 
• By Brenda Sandburg

Government claims Teva’s payments to two foundations to cover Copaxone copays violated Anti-Kickback statute. Teva is bucking settlement trend in DOJ’s industrywide investigation of sponsor ties to charitable foundations.

WASHINGTON, DC - MARCH 2018: Headquarters of the U.S. Justice Department. Art Deco aluminum torcheres at doorway. Renamed the Robert F. Kennedy Department of Justice Building in 2001.
Department of Justice sues Teva over charity copayments for Copaxone • Source: Shutterstock

Teva would apparently rather fight than settle US Department of Justice claims that charity copayments for its multiple sclerosis drug Copaxone (glatiramer) constitute illegal kickbacks.

The DoJ announced on 18 August that it had filed a False Claims Act complaint against Teva, alleging it used two foundations as conduits for hundreds of millions in kickbacks to Medicare patients while raising the price

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Legal & IP

After Jazz, Hikma Agrees $50m Settlement For ‘Most’ Xyrem ‘Pay-For-Delay’ Claims

 
• By Dean Rudge

Hikma said it would admit no wrongdoing or liability after reaching a preliminary settlement agreement over illicit ‘pay-for-delay’ claims involving its US version of Xyrem “that protects the company’s interests and provides clarity to our stakeholders.”

Viatris Pens Aprepitant Settlement Agreement After Kabi Loses Initial Patent Case

 
• By Dean Rudge

Viatris will look to introduce generic versions of Heron Therapeutics’ aprepitant brands, Cinvanti and Aponvie, around three years before patent expiry after settling litigation with the originator. Other court cases remain ongoing.

J&J Denied Injunction Over Private-Label Ustekinumab In US

 
• By Dave Wallace

Stelara originator J&J has been denied in its initial attempt to prevent Samsung Bioepis and ustekinumab biosimilar partner Sandoz from selling a private-label version of the product through a PBM in the US.

UK Forxiga SPCs Wiped Out As Trio Succeed With Plausibility Attack

 
• By Dean Rudge

Generic competition to AstraZeneca’s blockbuster SGLT2 inhibitor Forxiga (dapagliflozin) treatment for diabetes may hit England and Wales earlier than 2028 after a pair of SPCs were invalidated following proceedings initiated by a trio of generics manufacturers.

More from Generics Bulletin